We are live on ! Find out more
IBER.U

Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant
IBER.U

Delisted

IBER.U was delisted on the 1st of March, 2023.

Back to rankings

60 hedge funds and large institutions have $120M invested in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in 2021 Q1 according to their latest regulatory filings, with 60 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
60
Holders Change
+60
Holders Change %
–
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
60
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HP
Hartree Partners
New York
+$12.8M
2
MF
Magnetar Financial
Illinois
+$8.03M
3
Citadel Advisors
Citadel Advisors
Florida
+$7.75M
4
Millennium Management
Millennium Management
New York
+$5.25M
5
PAMP
Polar Asset Management Partners
Ontario, Canada
+$5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
1
Hartree Partners
New York
$12.7M +$12.8M +1,285,000 New
MF
2
Magnetar Financial
Illinois
$7.92M +$8.03M +802,800 New
Citadel Advisors
3
Citadel Advisors
Florida
$7.64M +$7.75M +775,000 New
Millennium Management
4
Millennium Management
New York
$5.18M +$5.25M +525,000 New
PAMP
5
Polar Asset Management Partners
Ontario, Canada
$4.93M +$5M +500,000 New
KC
6
Kepos Capital
New York
$4.88M +$4.95M +495,400 New
LA
7
Linden Advisors
New York
$4.44M +$4.5M +450,000 New
Marshall Wace
8
Marshall Wace
United Kingdom
$4.44M +$4.5M +450,000 New
SC
9
Sculptor Capital
New York
$4.19M +$4.25M +425,000 New
SCC
10
Spring Creek Capital
Kansas
$3.94M +$4M +400,000 New
VI
11
Vestcor Inc
New Brunswick, Canada
$3.94M +$4M +400,000 New
OP
12
Omni Partners
United Kingdom
$3.91M +$3.96M +396,350 New
SCM
13
Shaolin Capital Management
Florida
$3.9M +$3.95M +395,200 New
GCL
14
Glazer Capital LLC
New York
$3.46M +$3.51M +351,348 New
AC
15
Aristeia Capital
Connecticut
$3.45M +$3.5M +350,000 New
MCM
16
Moore Capital Management
New York
$2.96M +$3M +300,000 New
RCM
17
Radcliffe Capital Management
Pennsylvania
$2.96M +$3M +300,000 New
WC
18
Wealthspring Capital
New York
$2.89M +$2.93M +293,440 New
Nomura Holdings
19
Nomura Holdings
Japan
$2.77M +$2.81M +280,772 New
CCA
20
Castle Creek Arbitrage
Colorado
$2.5M +$2.53M +253,446 New
Calamos Advisors
21
Calamos Advisors
Illinois
$2.46M +$2.5M +250,000 New
PC
22
Periscope Capital
Ontario, Canada
$2.46M +$2.5M +250,000 New
Hudson Bay Capital Management
23
Hudson Bay Capital Management
Connecticut
$1.97M +$2M +200,000 New
MP
24
Mangrove Partners
Connecticut
$1.97M +$2M +200,000 New
Wells Fargo
25
Wells Fargo
California
$1.65M +$1.67M +167,484 New
1
2 3

IBER.U Hedge Fund Activity: Q1 2021 in Review

60 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) for Q1 2021, worth a combined $120M.

Buyers outnumbered sellers: 60 funds opened new IBER.U positions and 0 closed out — a net gain of 60 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Hartree Partners, opening a new position worth an estimated $12.8M.

  • 60 institutional investors held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $120M of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant stock for Q1 2021.
  • 60 funds opened new Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant positions in Q1 2021 and 0 closed out, a net change of +60 holders.
  • The largest Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant buyer in Q1 2021 was Hartree Partners, an estimated $12.8M added.

Based on aggregated 13F filings for Q1 2021.